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ELSEVIER
EDITORIAL
Minor Histocompatibility Antigens
From Τ Cell Recognition to
Peptide Identification
Eis Goulmy
PREFACE
For decades, minor histocompatibility antigens have
been regarded as disturbing entities readily used to ex-
plain unwanted immune reactivities in recipients of
MHC-matched bone marrow transplants Now that the
nature of these antigens IS being discovered, we may
apply the knowledge of these disturbing entities to the
benefit of human bone marrow transplantation
BACKGROUND
Bone marrow transplantation (BMT) in combination
with chemoradiotherapy is used as treatment of severe
aplastic anemia, leukemia, and other hematologic malig-
nancies The ideal transplant Situation is when BM donor
and recipient have identical MHC antigens and are
closely related Nonetheless, the results of clinical BMT
reveal that the selection of MHC-identical donors is not
a guarantee of avoidance of two of the major drawbacks
of allogeneic BMT, ι e , graft-versus-host disease
(GvHD) and leukemia relapse GvHD occurs, depending
on the age of recipient and the amount of Τ cell depletion
of the graft, in 15—35% of the HLA genotypically iden-
tical donoi/recipient situations [1,2] Τ cell depletion of
the donor marrow moculum shows a reduction in the
incidence and seventy of GvHD but coincides with an
increase of leukemia relapse On the one hand, mature Τ
cells present in the donor bone marrow inoculum are
essential for graR acceptance, on the other hand, they are
responsible for GvHD but most probably also cause the
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beneficial graft-versus-leukemia (GvL) effect Several
clinical studies indeed indicate a direct relationship be-
tween the GvL effect and acute and chronic GvHD
[3—5] In syngeneic BMT between identical twins, in
which their exists no major or minor Η antigen dispanty
and thus no alloreactivity can be induced, relapse rates
are as high as 46% [6] Recipients of autologous trans-
plants have also a high nsk of developmg recurrent
leukemia [7] In recipients of allogeneic BMT, the re-
lapse rates vary from 10% to 40% {8} Thus, one may
conclude that alloreactive donor Τ cells are probably
involved in antileukemia activities Assuming that the
human genome has an abundance of minor histocompat-
ibility (mH) loci resultmg in vanous minor histocom-
patibility antigen (mHag) incompatibilities between BM
donor and recipient, lt is tempting to State that mHags
are involved in both GvH and GvL activities
mHag· THE PAST AND THE PRESENT
It is not surpnsing that like the MHC-encoded major Η
Systems, the minor Η antigens have important biological
functions beside their role in organ and bone marrow
transplantation Their latter charactenstic, however, was
first discovered Both types of transplantation antigens
were descnbed by Snell and coworkers [9] and distin-
guished from one another on the basis of their respective
power in munne tumor graft rejection modeis £10] The
role of mHag in transplantation is best analyzed in an
HLA-matched Situation In humans, mHag studies have
predominantly been performed in the HLA-identical
BMT transplantation setting The efforts of several m-
vestigators have led to the Identification of a relatively
small number of mHags (for review, see {11]) Until
recently, mHags were Τ cell defined, both cytotoxic Τ
cells (CTL) and Τ helper (Th) cells recogmzing mHags in
Humin Immunology 54, 8-14 (1997)
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TABLE 1 Characteristics of human mHags H-Y and HA-1 to HA-5
mHag
H-Y
HA-1
HA-2
HA-3
HA 4
HA 5
Restnction
molecules
Vanous"
A2
A2
AI
A2
A2
Phenotype
frcquency (%)
50
69
95
88
16
7
Tissuc chstnbuuon
Broad*
Restncted + leukemic celis
Restncted + leukemic cells
Broad
Broad
Restncted + leukemic cells
TCR
usage
Variable
Vß 6 9
Variable
n t '
η t
η t
"HLA AI A2 Ι, Β7 and B60
Expression on all hematopoietic and nonhematopoietic ccll hneages
Fxpression restncted to the hematopoietic cell lineare
η t not tested
a classical MHC restnction fashion were desenbed [11}
Whether mHags really fdii to mduce antibody responses
has not been thoroughly mvestigated It IS noteworthy
that "autoantibodies, among which mHag-specific an-
tibodies may be present, can readily be observed after
HLA-identical BMT In sera of recipients of HLA geno-
typically identicai BM donations, we observed broadly
reactive antibodies against BM donor Τ and non-T cells
Some of these broadly reactive sera also showed reactivity
with autologous cells Α correlation between the oeeur-
rence of those antibodies and acute GvHD was sigmfi-
cant 26 of 31 patients with grades II—IV acute GvHD
had cytotoxic activity versus 11 of 21 patients with
grades 0-1 GvHD (p — 0 03) These antibodies did not
correlate significantly with chronic GvHD or with active
herpesvirus infections (J W Gratama et al , unpub-
hshed observations) Specificaüy, the presence of an
HLA-A2 restncted H-Y-specific antibody was desenbed
in the serum of a patient wherein CTLs with the same
specificity were observed {12}
In our laboratory, we performed detailed analyses on
the characteristics of a small number of mHags generated
from individuals pnmed in vivo by mHag-mismatched
bone marrow grafting or by blood transfusions [13] The
results of the genetic studies and tissue expression of the
male-specific mHag H-Y and of non-Y-hnked mHags
HA-1 to HA-5, as well as the Τ cell reeeptor (TcR) usage
of some of the mHag-specific CTL clones, are summa-
nzed in Table 1 As can be seen from this table, mHags
can be recognized in the context of different HLA alleles,
yet HLA-A2 1 is used frequently as the mHag-present-
mg molecule Whether this just reflects the relatively
high phenotype frequency of HLA-A2 1 (ι e , 49% in the
Caucasian population) or that HLA-A2 1 is optimally
equipped to serve as salver for peptide presentation IS
unclear In view of the latter supposition, it is of interest
that allelic differences exist in the interaction of MHC
class I molecules with transporters associated with anti-
gen processing [14} Among other HLA alleles, HLA-A2
shows a high affinity for Τ AP Indeed, Τ AP is required
for translocanon of cytosohe peptides, in addition, how-
ever, it is possible that TAP supports correct folding and
Joading of a subset of MHC class I molecules [14]
Phenotype frequency analyses were carned out for
mHags HA-1 to HA-5 These studies revealed that some
mHags, l e , HA-1, HA-2, and HA-3, appeared fre-
quently (69-95%), whereas others, l e , HA-4 and
HA-5, oecurred with lesser (7-16%) frequencies in the
healthy population [15] An analysis of their genetic
traits demonstrated a Mendelian mode of inhentance
[16] The CTL clones listed in Table 1 were also used to
analyze functional expression (ι e , the read-out is cell-
mediated lympholysis) of the mHags on vanous tissues
and cells [17] Differential expression was observed
some, ι e , H-Y, HA-3, and HA-4, are ubiquitously
expressed, whereas the expression of other mHags, ι e ,
HA-1 and HA-2, is limited to cells of the hematopoietic
lineage only [17] It is important to note that mHags
H-Y and HA-1 to HA-5 are expressed on clonogenic
normal and leukemic precursors cells as well on myeloid
and lymphoid leukemic cells isolated from the penpheral
blood [18, 19} Interestingly, when analyzing the TcR
usage for recognition of the HLA-A2/HA-1 ligand of 12
HLA-A2-restncted HA-1-specific CTL clones, we ob-
served a skewed TcR repertoire usage for the recognition
of mHag HA-1 in three unrelated patients [20] (Table
1) The latter results may be mdicative of a dominant
mHag-specific Τ cell response oecurring dunng the de-
velopment of GvHD after BMT
mHag: OBSTACLES IN BONE
MARROW TRANSPLANTATION
Prospective Analysis
Mixed epidermal cell eultures for detecting mHag dif-
ferences between HLA genotypically identicai BM do-
nors and recipients were reported by Vogelsang et al
[21} and Bagot et al [22] using a skin-explant model
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and a mixed epidermal cell—lymphocyte reaction, respec-
tively Dickinson et al used the levels of cytokine pro-
durtion in an in vitro skin explant model as a predictor
for acute GvHD before allogeneic BMT [23] Detection
of mHag differences between HLA genotypically ldenti-
cal BM donors and recipients by limiting dilution assays
has been reported by two groups of mvestigators The
assay IS based on the demonstration of the presence of
pre-BMT host-reactive precursor Τ cells and lts correla-
tion with the occurrence of GvHD [24, 25) The read-
out of the Τ cell precursor frequency analysis is IL-2
production of the responding cell population Thus, pre-
sumably, mHag-directed activities are measured in these
Th cell precursor assays It was shown that both CD4
positive and CD8 positive Τ cells participate in this
pre-BMT anti-host response [26] Detailed analysis of
the respective target structures recognized in this assay
remains to be done
Retrospective Analysis
Two recent retrospective analyses were reported descnb-
mg the influence of mHags on the development of acute
GvHD after transplantation of bone marrow from HLA-
ldentical sibhngs One report concerned our own analysis
of the influence of mHag HA-1, -2, -4, and -5 mis-
matches between HLA-identical BM donor/recipient
pairs (ι e , BM donor mHag negative and BM recipient
mHag positive) on the occurrence of acute GvHD of
grade II or more The results can be summanzed as
follows a mismatch for HA-1 and/or HA-2, -4, -5 was
sigmficantly associated with GvHD (p = 0 006) The
main effect of the significant association with the devel-
opment of GvHD appeared to be caused by an HA-1
mismatch, because a Single HA-1 mismatch between
donor and recipient reached a p value of 0 02 [27] The
latter association is seemingly in contradiction with the
absence of functional expression of mHag HA-1 on GvH
target tissue such as keratinocytes [17] (Table 1) How-
ever, HA-1 is clearly expressed on the professional anti-
gen-presenting cells (APC), ι e , dendritic cells (DC) and
Langerhans cells (LC) [28] The latter bone marrow-
derived APC are most potent in inducing alloreactive Τ
cell responses [29, 30] Thf conditiomng regime prior to
BMT will eliminate most of recipient's hematopoietic
cells, yet residual recipient cells including DC can be
present Host LC can persist for a long time after BMT
[31] So far, there exists little Information on the details
of the mechamsm(s) of GvH pathogenesis It is plausible
that the antigen presentation by the professional APCs
accounts for the primary induction of allo, ι e , mHag,
directed Τ cell activity and that subsequent local pro-
duction of inflammatory cytokines plays an important
role in tissue destruction Without doubt, cytokines do
play a significant role in the development of GvHD [32]
Besides cytokines, soluble factors such as soluble HLA
(sHLA) also possibly participate in the regulation of
(allo) immune responses Enhanced levels of sHLA, pos-
sibly as a consequence of the increased cytokine produc-
tion, are reported in GvHD patients [33, 34] On the
other hand, sHLA has the capacity to downregulate Τ
cell responses [35] Zavazava and Kronke showed that
sHLA-treated Fas-expressing Τ cells upregulate CD95-L
and subsequently undergo apoptosis [35]
The other retrospective study on the influence of
mismatched mHag on the development of acute GvHD
after HLA-identical BMT was reported by Behar et al
[36] This study dealt with allelic differences between
donor and recipient for the polymorphic adhesion mol-
ecule CD31 CD31 mismatches between BM donor and
recipient are associated with an increased risk of severe
GvHD disease of grade III or IV (p = 0 004) The
platelet-endothehal cell adhesion molecule 1 (CD31)
has broad expression it is constitutively expressed on
vascular endothelial cells, bone marrow stem cells, plate-
lets, and leukocytes [36] Interestingly, anti-CD31
monoclonal antibodies seemed to recognize the allelic
forms differentially No CD31-specific Τ cell responses
were reported, which separates this transplantation anti-
gen from the classical ones described in humans and
rodents earlier
Summanzing, these retrospective analyses demon-
strate, for the first time in humans, the putative influ-
ence of mHag differences on the outcome of bone marrow
transplants It is clear that these studies need confirma-
tion in larger groups of patients as well as by other
laboratones Nonetheless, incorporation of typing for
these mHags for BM donor selection in those cases where
more than one HLA-matched BM donor is available
seems justified
DO mHags PLAY Α ROLE IN
GRAFT-VERSUS-LEUKEMIA REACTIVITY?
In humans, evidence of an antileukemic effect associated
with allogeneic BMT is mainly based on clinical data
Regarding the in vitro immune studies on the GvH/GvL
mechanisms after BMT, it has been shown that alloreac-
tive donor Τ cells are responsible for GvHD and that
donor CTLs may eliminate leukemic cells by reacting
with alloantigens or tumor-specific antigens or both
[37] Besides donor-denved Τ cells reactive for ligands
(like mHags) that are shared by host PBLs and leukemic
cells [38-40], anti-host CTL responses that are specific
for either PHA blasts or leukemic cells have also been
observed in vitro [41—46] Some reports argue that GvH
and GvL activities can be dissected, whereas nonsepara-
ble effector cells that exhibit both activities also exist
Minor Histocompatibihty Antigens 11
TABLE 2 Identification of human mHaga
Restnction
molecule
HLA A2 1
HLAB7
HLA A2 1
mHag
HA 2
Η Υ
Η Υ
Peptide
(ηο of amino acids)
YIGEVLVSV (9 AA)
SPSVDKARAELÜ1 AA)
FIDSYICQV (9 AA)
Ongin
Nonfilamentous class I myosin,
involved in cell locomotion
and organeile transport
SMCY, transcnpnon factor for
spermatogenesis?
SMCY
[42] MHC unrestncted mechanisms may also operate to
elimmate leukemic cells [47—50]
Recently, donor lymphocyte transfusions (DLTs) as
treatment for relapsed leukemia appeared successful at
least for patients with CML (as reviewed in [51]) DLT
together with IFNa induced remissions in relapsed CML
patients after allogeneic BMT [8, 52, 53] Little IS
known about the mechanism(s) of the DLT-induced re-
mission in relapsed patients after BMT The therapeutic
efficacy of DLT in leukemia relapse after BMT is most
probably based on alloreactivity in the GvH direction,
because this donor leucocyte therapy is associated with a
sigmficant occurrence of marrow aplasia and GvHD
[54] It is likely that post-DLT, donor-denved anti-
mHag-specific CTLs potentiate a potent GvL effect As
stated earlier, in vitro studies with our mHag-specific
CTL clones provide an explanation for the GvL effect
mHag-specific CTL clones were shown to specifically
lyse freshly isolated myeloid and lymphoid leukemia
cells [19] and are capable of fully inhibiting the growth
of mHag-positive clonogenic myeloid leukemia precur-
sor cells [18]
mHags: FROM Τ CELL RECOGNITION TO
PEPTIDE IDENTIFICATION
Our mHag-specific Τ cell clones were indispensable for
the biochemical Identification of the mHag peptides
The biochemical Isolation procedure, ι e , affinity chro-
matography combined with microcapillary reversed-
phase high-performance liquid chromatography (HPLC)
coupled with electrospray lomzation mass spectrometry
[55], was successfully used for the Identification of
mHag peptides Α senes of mHag peptides is presently
known, the HLA-A2 1-restricted HA-2 and the HLA-
B7-restncted H-Y were the first ones descnbed [56, 57]
(Table 2) In addition, the amino acid composition of the
HLA-A2 1-restricted HA-1 (manuscnpt in preparation)
and the HLA~A2-restncted H-Y Τ cell epitopes have
been determined [58] As expected, mHags are naturally
processed peptides from intracellular proteins that asso-
ciate with MHC products [59] In addition, these pep-
tides are derived from genes with important biological
function [60, 61] (Table 2) To support the latter notion,
we mvestigated whether the mHags are evolutionarily
conserved between human and nonhuman primates In-
deed, the human HA-2 and H-Y peptides can be recog-
nued on the cell surface of nonhuman pnmate cells,
transfected with human class I genes, by our human
HA-2- and H-Y-specific class I restricted CTL clones
Furthermore, mHag peptides can be eluted from HLA-
A2 1 molecules expressed on the transfected nonhuman
pnmate cells This implies that the mHag peptides have
been conserved for at least 35 million years [62] More-
over, concurrent with the Identification of the human
H-Y peptide, a murine H-Y peptide was characterized
[63] and appeared to be derived from the same evolu-
tionarily conserved SMCY protein
mHags. USEFUL TOOLS IN BONE
MARROW TRANSPLANTATION
The putative clinical potentiality of mHags is presently
based on in vitro results of functional and clinical studies
performed in the past Bearmg this yet-restncted Infor-
mation in mind, some areas of clinical application are
worth mentioning The utihty for diagnosis in BM donor
selection is self-evident We are currently identifying the
mH genes so that mH typing on the molecular level can
be performed The pronounced immunogenic behavior of
mHag HA-1 on GvHD is, together with the recently
obtained amino acid composition, the basis for lmmu-
nomodulation of GvHD Designing mHag peptide
analogues that function as MHC or Τ cell receptor an-
tagonists might interfere with the harmful anti-host
mHag-directed Τ cell reactivities post-HLA-idenacal
BMT Our nonhuman pnmate study shows the possibil-
lty of using transgenic chimpanzees or rhesus monkeys
as a model for studying BMT-related reactivities such as
GvHD An animal model is also required for studying
the potential application of mHags with broad tissue
distribution, such as H-Y and HA-3, in induction of
tolerance in mHag-negative BM donors to prevent
GvHD and in mHag-negative BM recipients to prevent
rejection Achieving tolerance pnor to transplantation
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would decrease the necessity for usmg pharmacological
immunosuppression
Most promising is immunotherapy for leukemia usmg
CTLs specific for mHag peptide for the treatment of
refractory, residual, or relapsed leukemia The mHags
with restncted tissue distnbution (eg, HA-1 and
HA-2) are candidates for adoptive immunotherapy of
leukemia Upon transfusion, either pre-BMT as part of
the conditioning regimen or post-BMT as adjuvant ther-
apy, the mHag peptide-speafic CTLs will eliminate the
patient's leukemia cells and, lf of patient ongin, also the
patient's hematopoietic cells, but will spare the patient's
nonhematopoietic cells If necessary, subsequent donor
BMT will restore the patient's hematopoietic System
The ideal Situation is to generate mHag peptide CTLs ex
vivo from mHag-negative BM donors for mHag-positive
patients Α universal Option would be to generate "pre-
fab" mHag peptide-specific CTLs by the use of mHag-
negative healthy blood donors with common HLA-ho-
mozygous haplotypes Transduction of these CTLs with a
suicide gene makes elimination of the CTL possible in
case adverse effects occur Future research should also
focus on the possibihty of mHag donor immunization of
mHag-negative BM donors pnor to BMT to mHag-
positive high-nsk relapse recipients
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